Axa
ADAP

Axa’s Adaptimmune Therapeutics ADAP Stock Holding History

Axa’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-295,926
Closed -$1.98M – 1363
2017
Q4 		$1.98M Sell
295,926
-399,056
-57% -$3.08M 0.01% 865
2017
Q3 		$5.69M Sell
694,982
-172,479
-20% -$1.08M 0.02% 591
2017
Q2 		$3.9M Sell
867,461
-32,539
-4% -$170K 0.02% 664
2017
Q1 		$4.96M Buy
+900,000
New +$3.94M 0.02% 595

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Axa's ADAP Position: Q1 2018 in Review

Axa sold out of Adaptimmune Therapeutics (ADAP) in Q1 2018, closing a stake of 295,926 shares — an estimated $1.98M sold.

Axa first reported a position in ADAP in Q1 2017 and held it in 4 quarters. The position peaked at $5.69M in Q3 2017. 76 funds tracked by Wall St. Rank hold ADAP as of Q1 2018.

  • Axa reported no remaining Adaptimmune Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Axa sold 295,926 Adaptimmune Therapeutics shares in Q1 2018, an estimated $1.98M.
  • Axa first reported a position in Adaptimmune Therapeutics in Q1 2017 and held it in 4 quarters.
  • Axa's Adaptimmune Therapeutics position peaked at $5.69M in Q3 2017.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2018.

Based on Axa's 13F filing for Q1 2018, filed 14 May 2018.